CRANBURY, N.J., Sept. 23, 2016 /PRNewswire/ -- Palatin
Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company
developing targeted, receptor-specific peptide therapeutics for the
treatment of diseases with significant unmet medical need and
commercial potential, announced that a review of the neurobiology
and treatment efficacy of bremelanotide for hypoactive sexual
desire disorder ("HSDD") was presented at the International Society
for Sexual Medicine 20th World Meeting in Beijing, China.
Anita H. Clayton, M.D., of the
University of Virginia School of
Medicine, is lead author on the poster entitled "Bremelanotide: A
Review of Its Neurobiology and Treatment Efficacy for HSDD."
The poster addresses mechanisms of sexual response and the
pathophysiology of HSDD, and describes the potential of
bremelanotide to modulate brain pathways involved in sexual
response. The poster is available at Palatin's website,
www.palatin.com.
James G. Pfaus, Ph.D., of
Concordia University in Montreal,
Canada was co-author, together with Johna
Lucas, M.D., Carl Spana,
Ph.D. and Robert Jordan of
Palatin.
Palatin is developing bremelanotide, a centrally-mediated
medication, as a subcutaneous, on-demand treatment for
premenopausal women diagnosed with HSDD. Bremelanotide, which
is a melanocortin 4 receptor agonist drug candidate, is a synthetic
peptide analog of the naturally occurring hormone alpha-MSH
(melanocyte-stimulating hormone).
Last patient visits for the efficacy portion of Phase 3 trials
with bremelanotide for HSDD were completed in the third quarter of
calendar year 2016. Topline results are projected to be
released early fourth quarter of calendar year 2016.
Bremelanotide is dosed as an as-needed (not chronic) medical
treatment. This treatment is unlike flibanserin (ADDYI®) and
some other female sexual dysfunction treatments in development that
require daily administration and life style modifications.
About Palatin Technologies, Inc.
Palatin
Technologies, Inc. is a biopharmaceutical company developing
targeted, receptor-specific peptide therapeutics for the treatment
of diseases with significant unmet medical need and commercial
potential. Palatin's strategy is to develop products and then form
marketing collaborations with industry leaders in order to maximize
their commercial potential. For additional information
regarding Palatin, please visit Palatin's website at
www.Palatin.com.
Forward-looking Statements
Statements in this press
release that are not historical facts, including statements about
future expectations of Palatin Technologies, Inc., such as
statements about clinical trial results, potential actions by
regulatory agencies including the FDA, regulatory plans,
development programs, proposed indications for product candidates
and market potential for product candidates, are "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and as
that term is defined in the Private Securities Litigation Reform
Act of 1995. Palatin intends that such forward-looking statements
be subject to the safe harbors created thereby. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that could cause Palatin's actual
results to be materially different from its historical results or
from any results expressed or implied by such forward-looking
statements. Palatin's actual results may differ materially from
those discussed in the forward-looking statements for reasons
including, but not limited to, results of clinical trials,
regulatory actions by the FDA and the need for regulatory
approvals, Palatin's ability to fund development of its technology
and establish and successfully complete clinical trials, the length
of time and cost required to complete clinical trials and submit
applications for regulatory approvals, products developed by
competing pharmaceutical, biopharmaceutical and biotechnology
companies, commercial acceptance of Palatin's products, and other
factors discussed in Palatin's periodic filings with the Securities
and Exchange Commission. Palatin is not responsible for updating
for events that occur after the date of this press release.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/palatin-technologies-presents-bremelanotide-neurobiology-and-treatment-efficacy-review-at-world-meeting-on-sexual-medicine-300332936.html
SOURCE Palatin Technologies, Inc.